Long-term therapy of multiple sclerosis with fingolimod - results of 4.5-year extension study to TRANSFORMS

Abstract

The TRANFORMS clinical trial and its extension demonstrated reduced annualised relapse rate, disability progression, and improved magnetic resonance parameters in patients with relapsing remitting multiple sclerosis over the course of a 4.5-year follow-up. The study even found a higher proportion of patients with NEDA (no evidence of disease activity) the latter measure appearing to be the optimum treatment goal.

Safety profile of the therapy was satisfactory.

Keywords

• multiple sclerosis
• long term therapy
• fingolimod
• NEDA